Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients

Simona De Portu, L. G. Mantovan, A. Ravaioli, E. Tamburini, R. Bollina, C. Cozzi, A. M. Grimaldi, T. E. Testa, C. Bianchessi, G. Cartenì

Research output: Contribution to journalArticle

Abstract

The aim was to evaluate the cost of capecitabine vs conventional combination chemotherapics such as 5-fluo-rouracil (5-FU) for the treatment of metastatic colorectal cancer (mCRC) in Italy. The study was a multicenter, retrospective longitudinal treatment-cost analysis. Patients older than 18 years, diagnosis of mCRC and at least 3 completed cycles of chemotherapy with oral capecitabine or 5-FU also in association with other chemotherapic agents were enrolled. Direct healthcare resources attributable to mCRC treatment were quantified using 2007 prices and tariffs. The analysis was conducted from the National Health Service perspective with a 6-month time horizon. A total of 231 patients affected by mCRC (55% males; mean age 63.7±10.31 yrs) were studied. Total direct costs per patient per month in capecitabine and 5-FU groups were €1,001.66 ± €434.93 and €3,172.81 ± €1,232.37 respectively (p

Original languageEnglish
Pages (from-to)125-128
Number of pages4
JournalJournal of Chemotherapy
Volume22
Issue number2
Publication statusPublished - Apr 2010

Keywords

  • 5-fluorouracil
  • Capecitabine
  • Colorectal cancer
  • Cost of treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients'. Together they form a unique fingerprint.

  • Cite this

    De Portu, S., Mantovan, L. G., Ravaioli, A., Tamburini, E., Bollina, R., Cozzi, C., Grimaldi, A. M., Testa, T. E., Bianchessi, C., & Cartenì, G. (2010). Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. Journal of Chemotherapy, 22(2), 125-128.